Quoin Pharmaceuticals, Ltd. in brief
Quoin Pharmaceuticals, Ltd. is a listed company in the Biotechnology industry, based in Ashburn, Virginia, USA. Its shares trade under the symbol QNRX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Quoin Pharmaceuticals, Ltd.
We are a late-stage clinical specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases for which there are currently either no approved or very limited treatments or cures. Our lead product, QRX003, is under clinical development as a potential treatment for Netherton Syndrome, a rare hereditary genetic disease. QRX003 is entering pivotal registrational clinical testing under an open Investigational New Drug application with the Food and Drug Administration. We have opened six clinical sites in the United States along with international sites that are being opened in the UK, Spain, France and the Netherlands. QRX003 is currently being tested in seven pediatric NS patients in investigator-initiated studies in Ireland, Austria, the Netherlands and New Zealand. QRX003 is also being developed as a potential treatment for Peeling Skin Syndrome with the first subject being treated in New Zealand. We are in the process of expanding this study to include up to an additional five pediatric subjects. We entered into a Research Agreement with the Queensland University of Technology in Australia, under which we have obtained an option for a global license to QRX008 for the potential treatment of scleroderma, as well as a Research Agreement with The School of Pharmacy at University College Cork for the development of novel topical formulations of rapamycin (sirolimus) as potential treatments for a number of rare and orphan diseases for which there are either limited or no approved therapies or cures, including microcystic lymphatic malformations, venous malformations and angiofibromas among others. We have also entered into 9 commercial partnerships for QRX003 spanning 61 countries outside of our core commercial territories of the U.S., Western Europe and Japan.
From the company's annual report filed with the US SEC: read the report
Quoin Pharmaceuticals, Ltd. timeline
- 2016
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- ✎Renamed Cellect Biotechnology Ltd.Formerly Cellect Biomed Ltd..
- 🔔Initial public offering as Cellect Biotechnology Ltd.Final prospectus filed with the SEC on 1 August 2016; shares registered for exchange trading on 27 July 2016.
- 2021
- ✎Renamed Quoin Pharmaceuticals, Ltd.Formerly Cellect Biotechnology Ltd..
Events of Quoin Pharmaceuticals, Ltd. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
Not enough history yet.
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | — | $-16M | — |
| Dec 2024 | — | — | — | $-9M | — |
| Dec 2023 | — | — | — | $-9M | — |
| Dec 2022 | — | — | — | $-9M | — |
| Dec 2021 | — | — | — | $-21M | — |
| Dec 2020 | — | — | — | $-2M | — |
| Dec 2019 | — | — | — | $-2M | — |
| Dec 2017 | — | — | $-7M | $-8M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-14M | — | — | — | — |
| Dec 2024 | $-8M | — | — | — | — |
| Dec 2023 | $-8M | — | — | — | — |
| Dec 2022 | $-8M | — | — | — | — |
| Dec 2021 | $-6M | — | — | $-0.01 | — |
| Dec 2020 | $-1M | — | — | $-0.70 | — |
| Dec 2019 | $-1M | — | — | $-0.52 | — |
| Dec 2017 | $-5M | $0M | $-5M | — | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 20268-KCurrent reportShareholder vote
- Nov 6, 20268-KCurrent reportResults of operations
- Nov 5, 202610-QQuarterly report · period to Sep 2026
- Nov 4, 20268-KCurrent reportMaterial agreement
- Oct 20, 20268-KCurrent reportRegulation FD disclosure · Other events
- Oct 14, 20268-KCurrent reportRegulation FD disclosure · Other events
- Oct 2, 2026DEF 14AProxy statement
- Sep 22, 20268-KCurrent reportRegulation FD disclosure · Other events
- Sep 10, 20268-KCurrent reportRegulation FD disclosure · Other events
- Aug 28, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Regulation FD disclosure · Other events
- Aug 20, 20268-KCurrent reportDirectors or officers changed · Shareholder vote · Other events
- Aug 14, 20268-KCurrent reportResults of operations
Official filings of Quoin Pharmaceuticals, Ltd. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- —
- Net income
- $-16 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $20 M
- Total liabilities
- $7 M
- Total equity
- $13 M
As of December-2025
Top 25 institutional investors in Quoin Pharmaceuticals, Ltd.#
| # | Institution | Shares held | Change (shares) | Value | Filed |
|---|---|---|---|---|---|
| 1 | Stonepine Capital Management, LLC | 252,434 | +52,948 (+26.54%) | $1 M | Nov 13, 2026 |
| 2 | Nantahala Capital Management, LLC | 236,234 | New | $1 M | Nov 13, 2026 |
| 3 | Sphera Funds Management LTD. | 236,234 | New | $1 M | Nov 16, 2026 |
| 4 | AIGH Capital Management LLC | 236,234 | +166,234 (+237.48%) | $1 M | Nov 2, 2026 |
| 5 | Stempoint Capital LP | 236,234 | New | $1 M | Nov 16, 2026 |
| 6 | Millennium Management LLC | 236,227 | +123,904 (+110.31%) | $1 M | Nov 16, 2026 |
| 7 | Ikarian Capital, LLC | 211,538 | 0 (0.00%) | $1 M | Nov 16, 2026 |
| 8 | Empery Asset Management, LP | 204,910 | New | $1 M | Nov 16, 2026 |
| 9 | Dauntless Investment Group, LLC | 193,937 | -21,050 (-9.79%) | $1 M | Nov 16, 2026 |
| 10 | J. Goldman & Co LP | 190,192 | New | $1 M | Nov 16, 2026 |
| 11 | Diadema Partners LP | 146,446 | New | $1 M | Nov 16, 2026 |
| 12 | DAFNA Capital Management LLC | 132,156 | New | $1 M | Nov 16, 2026 |
| 13 | Boothbay Fund Management, LLC | 59,838 | 0 (0.00%) | $0 M | Nov 16, 2026 |
| 14 | Nano Cap New Millennium Growth Fund L P | 50,000 | New | $0 M | Nov 13, 2026 |
| 15 | Citadel Advisors LLC | 20,307 | New | $0 M | Nov 16, 2026 |
| 16 | Jane Street Group, LLC | 19,456 | New | $0 M | Nov 12, 2026 |
| 17 | Morgan Stanley | 8,000 | 0 (0.00%) | $0 M | Nov 13, 2026 |
| 18 | Rhumbline Advisers | 3,169 | +837 (+35.89%) | $0 M | Nov 10, 2026 |
| 19 | GAMMA Investing LLC | 3,116 | +2,677 (+609.79%) | $0 M | Oct 8, 2026 |
| 20 | Nuveen, LLC | 437 | New | $0 M | Nov 10, 2026 |
| 21 | Arax Advisory Partners | 171 | New | $0 M | Nov 12, 2026 |
| 22 | Tower Research Capital LLC (TRC) | 136 | New | $0 M | Nov 16, 2026 |
| 23 | SBI Securities Co., Ltd. | 128 | -227 (-63.94%) | $0 M | Oct 22, 2026 |
| 24 | Caitong International Asset Management Co., Ltd | 9 | New | $0 M | Oct 29, 2026 |
| 25 | Nisa Investment Advisors, LLC | 4 | New | $0 M | Oct 20, 2026 |
Mutual funds holding Quoin Pharmaceuticals, Ltd.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 abrdn World Healthcare Fundabrdn Inc. | 40,400 | $0 M | 0.06% | 0.03% | no change | Jun 30, 2026 |
| 🇺🇸 abrdn Life Sciences Investorsabrdn Inc. | 34,600 | $0 M | 0.05% | 0.02% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 2 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Quoin Pharmaceuticals, Ltd.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Denise P. CarterChief Operating Officer, Director | Buy | +20,490 | $4.880 | — | 37,709 | Form 4 |
| filed | Anthony James CulverwellDirector | Buy | +6,146 | $4.880 | $30 K | 40,364 | Form 4 |
| filed | Michael MyersChief Executive Officer, Director | Buy | +20,490 | $4.880 | $100 K | 37,713 | Form 4 |
| filed | Sally Bridget LawlorChief Financial Officer | Buy | +10,244 | $4.880 | $50 K | 10,684 | Form 4 |
| filed | Dennis LangerDirector | Grant or award | +34,534 | $5.150 | $178 K | 56,243 | Form 4 |
| filed | Anthony James CulverwellDirector | Grant or award | +31,352 | $5.150 | $161 K | 34,218 | Form 4 |
| filed | Dennis LangerDirector | Buy | +15,152 | $8.490 | $129 K | 15,153 | Form 4 |
| filed | Michael MyersChief Executive Officer, Director | Buy | +555,556 | $0.450 | $250 K | 602,808 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Quoin Pharmaceuticals, Ltd.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1.67-for-1 split ; 12.5-for-1 split
Trading halts
- 2026-11-17 15:19 UTC, code LUDP, resumed 15:24 UTC
- 2026-06-24 14:06 UTC, code LUDP, resumed 14:11 UTC
- 2026-06-24 13:57 UTC, code LUDP, resumed 14:02 UTC
- 2026-03-25 13:42 UTC, code LUDP, resumed 13:47 UTC
- 2026-03-25 13:33 UTC, code LUDP, resumed 13:38 UTC
Fails to deliver
- : 774 shares at $4.16
- : 666 shares at $4.18
- : 465 shares at $4.00
- : 460 shares at $4.01
- : 22,887 shares at $3.98
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Quoin Pharmaceuticals, Ltd. scorecard#
Passes 1 of the 6 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- ✗Net income higher than five years earlier-$16 M-$16 M in fiscal 2025 against -$2 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$16 MNet income -$16 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-141.6%-141.6% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities3.6×Current ratio 3.61 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Quoin Pharmaceuticals, Ltd.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in thousands of each column's currency; per-share figures in the column's currency; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 · USD | FY 2024to Dec 31, 2024 · USD | FY 2023to Dec 31, 2023 · USD | FY 2022to Dec 31, 2022 · USD | FY 2021to Dec 31, 2021 · USD | FY 2020to Dec 31, 2020 · USD | FY 2019to Dec 31, 2019 · USD | FY 2018to Dec 31, 2018 · ILS | FY 2017to Dec 31, 2017 · ILS | FY 2016to Dec 31, 2016 · ILS |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | — | — | — | — | 0—— | 0—— | 0—— | — | — | — | |
| Research and development | 9,803+172%— | 3,603+8.9%— | 3,308+23.8%— | 2,673+71.0%— | 1,563+540%— | 244r1,830+435%— | 46r−3,508—— | 13,513r13,513—— | −11,503r11,503−239%— | 8,256—— | |
| Selling, general and administrative | 6,488+9.5%— | 5,926−2.4%— | 6,071−7.8%— | 6,585+46.3%— | 4,500+216%— | 1,426−5.9%— | 1,515—— | 3,730+8.3%— | 3,444+165%— | 1,299—— | |
| Total costs and expenses | — | — | — | — | — | — | — | 29,247+19.7%— | 24,433+53.2%— | 15,944—— | |
| Operating income | — | — | — | — | — | −4,353—— | −6,462—— | −29,247—— | −24,433—— | −15,944—— | |
| Interest and finance income | 482−13.7%— | 558—— | — | — | — | — | 2,024—— | 9,154+8963%— | 101−84.7%— | 660—— | |
| Interest expense and finance costs | — | — | — | — | 1,090+2219%— | 47r1,270−88.9%— | 425—— | 20−99.5%— | 3,892+11694%— | 33—— | |
| Other non-operating income (expense) | 486−14.1%— | 566−18.2%— | 692—— | −124—— | −15,400—— | −425—— | — | — | — | — | |
| Income before tax | −15,805—— | −8,962—— | — | — | — | — | — | — | — | — | |
| Net income including minority interests | −15,805—— | −8,962—— | −8,687—— | −9,381—— | −21,463—— | −2,095r−5,623—— | −1,560r−4,863—— | −20,113—— | −28,224—— | −15,317—— | |
| Net income attributable to shareholders | −15,805—— | −8,962—— | −8,687—— | −9,381—— | −21,463—— | −2,095—— | −1,560—— | — | — | — | |
| Earnings per share, basic | — | — | — | — | -0.01—— | -0.70—— | -0.52—— | — | — | — | |
| Earnings per share, diluted | — | — | — | — | -0.01—— | -0.70—— | -0.52—— | — | — | — | |
| Shares, weighted average (basic) | — | — | — | — | 1,585+31.9%— | 1,201r3680.0%— | 1,201r213—— | 129+15.6%— | 112+22.9%— | 91—— | |
| Shares, weighted average (diluted) | — | — | — | — | 1,585+31.9%— | 1,2010.0%— | 1,201—— | — | — | — | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 3,818+5.4%18.7% | 3,623+50.9%23.1% | 2,401−16.1%19.7% | 2,861−61.8%19.8% | 7,483+2211%80.0% | 324r5,277−94.3%23.5% | 5,632r5,239—91.3% | 17,809+29.7%86.3% | 13,734+119%45.2% | 6,279—18.5% | |
| Short-term investments | 14,927+43.1%73.2% | 10,434—66.4% | — | — | — | — | — | — | — | — | |
| Receivables | — | — | — | — | — | 5.0+66.7%0.4% | 3.0—0.0% | 30—0.1% | — | — | |
| Other current assets | 1,262+45.2%6.2% | 869+47.1%5.5% | 591+14.4%4.9% | 517—3.6% | — | — | — | — | — | — | |
| Current assets | 20,007+34.0%98.1% | 14,926+32.3%95.0% | 11,286−15.6%92.7% | 13,370+63.1%92.5% | 8,198r8,498+1662%87.6% | 465r5,365−91.3%33.8% | 5,375—87.1% | 18,625−34.8%90.2% | 28,551−11.9%94.0% | 32,397—95.5% | |
| Property, plant and equipment | — | — | — | — | — | 384+2.9%27.9% | 373—6.0% | 1,544+14.9%7.5% | 1,344−2.1%4.4% | 1,373—4.0% | |
| Right-of-use (leased) assets | — | — | — | — | — | — | — | 1,614—7.8% | — | — | |
| Other intangible assets | 383−20.7%1.9% | 483−17.1%3.1% | 583−17.2%4.8% | 705−12.9%4.9% | 809−11.4%8.6% | 913—66.2% | — | — | — | — | |
| Non-current assets | — | — | — | — | — | 725−8.7%52.6% | 794—12.9% | 2,013+10.5%9.8% | 1,822+20.4%6.0% | 1,513—4.5% | |
| Total assets | 20,391+29.8%100% | 15,709+29.1%100% | 12,169−15.8%100% | 14,458+54.5%100% | 9,357+579%100% | 1,378r6,090−77.7%100% | 6,169—100% | 20,638−32.1%100% | 30,373−10.4%100% | 33,910—100% | |
| Accounts payable | 1,262+39.4%6.2% | 906+72.0%5.8% | 527−13.1%4.3% | 606−34.4%4.2% | 923—9.9% | — | — | — | — | — | |
| Current liabilities | 5,547+32.7%27.2% | 4,181+16.7%26.6% | 3,581+1.5%29.4% | 3,528−22.9%24.4% | 4,576+393%48.9% | 929−11.7%67.4% | 1,052—17.1% | 4,899+19.5%23.7% | 4,099+17.6%13.5% | 3,485—10.3% | |
| Lease liabilities (non-current) | — | — | — | — | — | 122−37.8%8.9% | 196—3.2% | — | — | — | |
| Non-current liabilities | — | — | — | — | — | 502−39.1%36.4% | 824—13.4% | 1,816—8.8% | — | — | |
| Total liabilities | 7,271+11.8%35.7% | 6,505−0.0%41.4% | 6,505−7.7%53.5% | 7,051−18.9%48.8% | 8,700+9.0%93.0% | 7,985—580% | — | — | — | — | |
| Retained earnings | −70,970—−348% | −55,166—−351% | −46,203—−380% | −37,517—−259% | −28,070—−300% | −6,607r−36,996—−480% | −29,185—−473% | −84,056—−407% | −63,943—−211% | −35,719—−105% | |
| Shareholders' equity | 13,120+42.5%64.3% | 9,205+62.5%58.6% | 5,664−23.5%46.5% | 7,407+1027%51.2% | 657—7.0% | −6,607—−480% | −4,512—−73.1% | — | — | — | |
| Total equity | — | — | — | — | — | 4,659+8.5%338% | 4,293—69.6% | 13,923−26.1%67.5% | 18,852−33.8%62.1% | 28,487—84.0% | |
| Total liabilities and equity | 20,391+29.8%100% | 15,709+29.1%100% | 12,169−15.8%100% | 14,458+54.5%100% | 9,357+579%100% | 1,378r6,090−77.7%100% | 6,169—100% | 20,638−32.1%100% | 30,373−10.4%100% | 33,910—100% | |
| Shares outstanding | 52+486%— | 8.9+806%— | 1.0+144%— | 0.4r24,233−100.0%— | 3,355+179%— | 1,201r391+436%— | 224—— | 130+8.5%— | 120r120+11.7%— | 108—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | — | — | 109+0.9%— | 108—— | 459+23.4%— | 372+6.3%— | 350—— | |
| Share-based compensation | 1,147−8.9%— | 1,259+15.0%— | 1,095+43.3%— | 764—— | 0−100%— | 229−70.8%— | 784—— | 4,537−15.7%— | 5,384+247%— | 1,552—— | |
| Cash from operating activities | −13,541—— | −7,857—— | −7,864—— | −8,481—— | −5,720—— | −1,339r−4,816—— | −1,299r−5,884—— | −23,635—— | −17,770—— | −14,412—— | |
| Capital expenditure | — | — | — | — | — | −103—— | −36—— | −656—— | −266—— | −1,265—— | |
| Cash from investing activities | −4,278—— | −1,888−186%— | 2,188—— | −10,149—— | −625—— | −125r−90—— | −31—— | 13,708+35.8%— | 10,091—— | −18,012—— | |
| Shares issued | 18,614+60.9%— | 11,568—— | — | — | — | 2,860−55.9%— | 6,479—— | 12,360−14.1%— | 14,381−58.8%— | 34,917—— | |
| Cash from financing activities | 18,014+64.2%— | 10,968+110%— | 5,217−62.8%— | 14,008+3.7%— | 13,504+655%— | 1,787r4,158+37.6%— | 1,299r6,328—— | 12,759−19.3%— | 15,813−54.7%— | 34,924—— | |
| Exchange-rate effect on cash | — | — | — | — | — | 393—— | −327—— | 1,243—— | −679—— | −134—— | |
| Change in cash | 195−84.1%— | 1,222—— | — | — | — | −355−513%— | 86—— | 4,075−45.3%— | 7,455+215%— | 2,366—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 20-F | 20-F | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 12,813+65.2%— | 2,656+16.4%— | 3,627+76.9%— | 3,434+44.6%— | 3,097*+195%— | 2,281+111%— | 2,051+249%— | 2,374+168%— | 1,050r1,070*+26.2%— | 1,080r1,170—— | 588r519—— | 885r843—— | 832*—— | |
| Selling, general and administrative | 7,235+12.7%— | 2,267+30.4%— | 1,846+6.0%— | 1,697+7.2%— | 1,424*+5.1%— | 1,739+20.0%— | 1,743+12.5%— | 1,583+0.6%— | 1,355r1,335*−2.2%— | 1,448r1,358—— | 1,550r1,618—— | 1,573r1,615—— | 1,385*—— | |
| Interest and finance income | 545—— | 125+101%— | 101−2.2%— | 147+1.3%— | 172*—— | 62—— | 103—— | 145—— | — | — | — | — | — | |
| Other non-operating income (expense) | 460+12.9%— | 52−27.2%— | 103+5.4%— | 133−7.9%— | 172*+83.5%— | 72−59.7%— | 97−40.4%— | 145+10.7%— | 94*−44.1%— | 178—— | 163—— | 131—— | 168*—— | |
| Net income including minority interests | −19,588—— | −4,871*—— | −5,371*—— | −4,998—— | −4,348*—— | −3,948*—— | −3,696*—— | −3,812—— | −2,311*—— | −2,350*—— | −1,974*—— | −2,327—— | −2,050*—— | |
| Net income attributable to shareholders | −19,588—— | −4,871—— | −5,371—— | −4,998—— | −4,348*—— | −3,948—— | −3,696—— | −3,812—— | −2,311*—— | −2,350—— | −1,974—— | −2,327—— | −2,050*—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 10,100—29.1% | 10,100+452%29.1% | 3,846+130%32.1% | 3,125−18.3%19.9% | 3,818+5.4%18.7% | 1,831−41.3%28.5% | 1,668−41.4%18.7% | 3,822+108%29.5% | 3,623+50.9%23.1% | 3,117—27.4% | 2,845—20.2% | 1,834—11.4% | 2,401—19.7% | |
| Short-term investments | 23,084—66.4% | 23,084—66.4% | 6,954—58.1% | 10,919—69.6% | 14,927+43.1%73.2% | — | — | — | 10,434—66.4% | — | — | — | — | |
| Other current assets | 1,217—3.5% | 1,217+102%3.5% | 836+21.4%7.0% | 1,291+36.8%8.2% | 1,262+45.2%6.2% | 603+216%9.4% | 689+5.9%7.7% | 944+64.2%7.3% | 869+47.1%5.5% | 191—1.7% | 651—4.6% | 575—3.6% | 591—4.9% | |
| Current assets | 34,400—99.0% | 34,400+472%99.0% | 11,636+37.2%97.2% | 15,335+22.7%97.7% | 20,007+34.0%98.1% | 6,015−42.7%93.6% | 8,479−35.9%95.1% | 12,497−18.1%96.5% | 14,926+32.3%95.0% | 10,497—92.2% | 13,221—94.1% | 15,265—94.7% | 11,286—92.7% | |
| Other intangible assets | 308—0.9% | 308−24.5%0.9% | 333−23.1%2.8% | 358−21.8%2.3% | 383−20.7%1.9% | 408−19.7%6.4% | 433−18.7%4.9% | 458−17.9%3.5% | 483−17.1%3.1% | 508—4.5% | 533—3.8% | 558—3.5% | 583—4.8% | |
| Total assets | 34,747—100% | 34,747+441%100% | 11,970+34.3%100% | 15,693+21.1%100% | 20,391+29.8%100% | 6,424−43.6%100% | 8,913−36.6%100% | 12,955−19.6%100% | 15,709+29.1%100% | 11,389—100% | 14,055—100% | 16,123—100% | 12,169—100% | |
| Accounts payable | 1,578—4.5% | 1,578−15.2%4.5% | 3,110+256%26.0% | 1,776+176%11.3% | 1,262+39.4%6.2% | 1,861+736%29.0% | 874+6.6%9.8% | 644+79.6%5.0% | 906+72.0%5.8% | 223—2.0% | 820—5.8% | 359—2.2% | 527—4.3% | |
| Current liabilities | 4,776—13.7% | 4,776−17.2%13.7% | 6,613+52.5%55.2% | 5,346+10.1%34.1% | 5,547+32.7%27.2% | 5,765+65.9%89.7% | 4,337+9.7%48.7% | 4,856+15.0%37.5% | 4,181+16.7%26.6% | 3,474—30.5% | 3,953—28.1% | 4,224—26.2% | 3,581—29.4% | |
| Total liabilities | 6,049—17.4% | 6,049−20.8%17.4% | 8,037+26.3%67.1% | 6,920−1.6%44.1% | 7,271+11.8%35.7% | 7,638+28.4%119% | 6,361−3.3%71.4% | 7,029+0.5%54.3% | 6,505−0.0%41.4% | 5,947—52.2% | 6,576—46.8% | 6,998—43.4% | 6,505—53.5% | |
| Retained earnings | −86,210—−248% | −86,210—−248% | −81,339—−680% | −75,968—−484% | −70,970—−348% | −66,622—−1037% | −62,674—−703% | −58,978—−455% | −55,166—−351% | −52,855—−464% | −50,505—−359% | −48,531—−301% | −46,203—−380% | |
| Shareholders' equity | 28,698—82.6% | 28,698—82.6% | 3,933+54.1%32.9% | 8,773+48.0%55.9% | 13,120+42.5%64.3% | −1,215−122%−18.9% | 2,551−65.9%28.6% | 5,926−35.1%45.7% | 9,205+62.5%58.6% | 5,442—47.8% | 7,478—53.2% | 9,126—56.6% | 5,664—46.5% | |
| Total liabilities and equity | 34,747—100% | 34,747+441%100% | 11,970+34.3%100% | 15,693+21.1%100% | 20,391+29.8%100% | 6,424−43.6%100% | 8,913−36.6%100% | 12,955−19.6%100% | 15,709+29.1%100% | 11,389—100% | 14,055—100% | 16,123—100% | 12,169—100% | |
| Shares outstanding | 168—— | 168+717%— | 70+241%— | 69+233%— | 52+486%— | 21+308%— | 21+417%— | 21+442%— | 8.9+806%— | 5.0—— | 4.0—— | 3.8—— | 1.0—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 1,744+46.6%— | 484+166%— | 532+65.7%— | 445+23.4%— | 283*−13.2%— | 182−41.9%— | 321+2.6%— | 360+17.6%— | 326*+8.7%— | 313—— | 313—— | 306—— | 300*—— | |
| Cash from operating activities | −18,818—— | −5,770*—— | −3,144*—— | −4,869—— | −5,035*—— | −2,225*—— | −3,686*—— | −2,594—— | −2,237*—— | −2,179*—— | −2,007*—— | −1,434—— | −3,224*—— | |
| Cash from investing activities | −19,221−604%— | −16,089*−734%— | 4,018*+139%— | 4,119+48.7%— | −11,268*—— | 2,538*−2.4%— | 1,683*−46.7%— | 2,770—— | −3,178*−220%— | 2,601*—— | 3,155*—— | −4,466—— | 2,644*—— | |
| Cash from financing activities | 46,306+720%— | 28,111*—— | −152*—— | 56+144%— | 18,291*+209%— | −150*—— | −150*—— | 23−99.6%— | 5,921*—— | −150*—— | −136*—— | 5,332—— | −183*—— | |
| Change in cash | 8,269—— | 6,254*+3751%— | 721*—— | −694−449%— | 1,987*—— | 162*—— | −2,154*—— | 199—— | — | — | — | — | — | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Quoin Pharmaceuticals, Ltd.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 6 · Material agreement 3 · Unregistered share sale 2 · Shareholder rights changed 1 · Shareholder vote 3 · Results announced 7
| Filed | What happened | Filing |
|---|---|---|
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersShareholder rights changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2026 | $50 M | Private placement after listing | $50 to $250 million | 33 | equity, options | SEC |
| Oct 2025 | $105 M | Private placement after listing | $50 to $250 million | 27 | equity, options | SEC |
| Jan 2018 | $4 M | Private placement after listing | $2 to $10 million | 3 | options | SEC |
| Sep 2017 | $4 M | No. 1 | $2 to $10 million | 18 | options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Quoin Pharmaceuticals, Ltd.#
$60 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues, medical/disease research/clinical labs and pharmacy.
- Health Issues3 reports
- Medical/Disease Research/Clinical Labs3 reports
- Pharmacy3 reports
Lobbying firms hired in 2025
Forward Global $60 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $60 K | — | 3 |
| 2025 | $60 K | — | 4 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Quoin Pharmaceuticals, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Quoin Pharmaceuticals, Ltd.#
1 labor condition applications certified in fiscal 2025 for 1 positions.
| Job title | Positions | Median wage offered |
|---|---|---|
| DirectorFinancial Managers | 1 | — |
Where: Brooklyn, NY 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2025 | 1 | 1 | — | 1 |
| FY2023 | 1 | 1 | — | 1 |
| FY2021 | 1 | 1 | — | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Quoin Pharmaceuticals Inc.
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Quoin Pharmaceuticals, Ltd.🇺🇸 | — | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Quoin Pharmaceuticals, Ltd.? Verify and update this profile — free
Show Quoin Pharmaceuticals, Ltd.'s ranking on your website Get the badge
The badge updates itself as the ranking changes.